Approaches to functionally validate candidate genetic variants involved in colorectal cancer predisposition by Bonjoch Gassol, Laia et al.
Contents lists available at ScienceDirect
Molecular Aspects of Medicine
journal homepage: www.elsevier.com/locate/mam
Approaches to functionally validate candidate genetic variants involved in
colorectal cancer predisposition
Laia Bonjocha, Pilar Murb,c, Coral Arnau-Collella, Gardenia Vargas-Parrab,c, Bahar Shamlood,
Sebastià Franch-Expósitoa, Marta Pinedab,c, Gabriel Capellàb,c, Batu Ermane, Sergi Castellví-Bela,∗
aGastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de
Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain
bHereditary Cancer Program, Catalan Institute of Oncology, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), ONCOBELL Program, L'Hospitalet de Llobregat,
Barcelona, Spain
c Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain
dMolecular Biology, Genetics, and Bioengineering Department, Legacy Research Institute, Portland, OR, USA
eMolecular Biology, Genetics and Bioengineering Program, Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey








A B S T R A C T
Most next generation sequencing (NGS) studies identified candidate genetic variants predisposing to colorectal
cancer (CRC) but do not tackle its functional interpretation to unequivocally recognize a new hereditary CRC
gene. Besides, germline variants in already established hereditary CRC-predisposing genes or somatic variants
share the same need when trying to categorize those with relevant significance. Functional genomics approaches
have an important role in identifying the causal links between genetic architecture and phenotypes, in order to
decipher cellular function in health and disease. Therefore, functional interpretation of identified genetic var-
iants by NGS platforms is now essential. Available approaches nowadays include bioinformatics, cell and mo-
lecular biology and animal models. Recent advances, such as the CRISPR-Cas9, ZFN and TALEN systems, have
been already used as a powerful tool with this objective. However, the use of cell lines is of limited value due to
the CRC heterogeneity and its close interaction with microenvironment. Access to tridimensional cultures or
organoids and xenograft models that mimic the in vivo tissue architecture could revolutionize functional ana-
lysis. This review will focus on the application of state-of-the-art functional studies to better tackle new genes
involved in germline predisposition to this neoplasm.
1. Introduction
As for other complex diseases, colorectal cancer (CRC) is caused by
both genetic and environmental factors. Twin studies showed that
around 13%–30% of the variation in CRC susceptibility involves in-
herited genetic differences (Lichtenstein et al., 2000; Frank et al.,
2017). Some of the known CRC-predisposing factors were already dis-
covered in the past decade (Peters et al., 2015). Next generation se-
quencing (NGS) has revolutionized our ability to read information from
the genome, including the DNA sequence itself, the state of the tran-
scriptome and the epigenome, among others (Casey et al., 2013). NGS
has tremendously improved the identification of disease candidate ge-
netic variants. However, most NGS studies did not tackle its functional
interpretation of these variants to unequivocally recognize a new her-
editary CRC gene (Valle, 2017). Also, similarly to the germline
counterpart, the same functional interpretation difficulty is en-
countered when somatic studies are pursued to identify clinically re-
levant variants (Ng et al., 2018). Functional interpretation of the
identified variants involved in germline predisposition and somatic
studies is essential to establish an unambiguous link to disease predis-
position or progression. Available approaches nowadays include
bioinformatics, cell and molecular biology and animal models. Recent
advances, such as the CRISPR-Cas9 system, have already showed high
potential to be used in this direction (Mali et al., 2013a; Komor et al.,
2017).
Functional studies of genetic variants suspected of being involved in
predisposition to disease are still scarce in most research or hospital
centers where NGS technologies are applied. However, they are im-
perative for the correct interpretation of results in the fields of research
and clinical diagnosis. Aim to generalize and facilitate this type of
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studies, tools have been recently developed that allow carrying them
out massively and in parallel (Wei et al., 2014).
Functional genomics approaches have an important role in identi-
fying the causal links between genetic architecture and phenotypes, in
order to decipher cellular function in health and disease. Therefore,
functional interpretation of genetic variants identified by NGS plat-
forms is now essential. It should be mentioned that the use of cell lines
is of limited value due to the CRC heterogeneity and its close interaction
with microenvironment. Therefore, access to tridimensional (3D) cul-
tures and xenograft models that mimic the in vivo tissue architecture
may revolutionize functional analysis (Ribatti, 2014; Dutta et al.,
2017).
On the other hand, the emergence of CRISPR/Cas9 technology is
allowing a much more fluid modification of the genome at the time to
introduce the genetic variants to be studied and for its subsequent
functional dissection in cellular models. Moreover, 3D models permit
culture and outgrowth of intestinal crypt cells into organoids (Dutta
et al., 2017), recapitulating the physiology, shape, dynamics and cell
make-up of the intestinal epithelium (Grabinger et al., 2014). In addi-
tion, the chorioallantoic membrane assay is a highly reproducible xe-
nograft model (Ribatti, 2014). Such models play an important role in
the screening and evaluation of new biomarkers and their functional
characterization. Besides, genes of interest can be knocked out and their
functional effects on the gut can be studied (Mizutani et al., 2017).
The present chapter aims at reviewing the current knowledge and
available tools to better characterize the functional effect of genetic
variation. Particularly, it will focus on the application of state-of-the-art
functional studies to better tackle genes involved in germline predis-
position to CRC.
2. Bioinformatics
The use of exome and genome sequencing to unveil new variants
involved in disease genetics faces a relentless bottleneck when variant
identification studies stumble upon large lists of candidate variants
waiting to be prioritized (Cline and Karchin, 2011). Prior to functional
studies, and due to time-consume and economical high costs of these
experiments, variant impact potentiality must be assessed (Quintáns
et al., 2014; Tang and Thomas, 2016). Multiple bioinformatics tools to
approach this issue have been developed, enabling annotation, scoring
and classification of variants to comprehensively estimate the deleter-
iousness of human genetic variants (Niroula and Vihinen, 2016). Spe-
cially, single nucleotide variants (SNVs) at coding regions have been the
main focus when developing tools to predict a functional impact, being
rare non-synonymous variants intrinsically more plausible diseases
candidates (Cooper and Shendure, 2011; Li et al., 2013).
Prioritization and prediction tools assume that disease may arise
through a change in protein's amino acid sequence and collaterally
affecting its function (Mooney et al., 2010; Tang and Thomas, 2016).
Thus, prediction tools may use different perspectives to approach this
premise: (1) direct protein structure inspection, where variant effect is
predicted from its possible effects on protein stability and function; or
(2) sequence comparison studying either nucleotide sequence or amino
acid sequences from different species, reflecting the effects of negative
natural selection by noticing those positions that display evolutionary
conservation among homologs (Cline and Karchin, 2011). However,
protein structure availability is mandatory for those structure-based
methods. Therefore, sequence conservation-based tools have been used
extensively and great efforts have been made to improve these methods,
arising multiple tools during the last two decades (Tang and Thomas,
2016). Table 1 summarizes bioinformatics tools available for patho-
genicity prediction of genetic variants. Renowned methods such as SIFT
(Stone and Sidow, 2005), PANTHER (Thomas et al., 2003), polyPhen2
(Adzhubei et al., 2010), GERP (Cooper et al., 2005) or LRT (Chun and
Fay, 2009) have been extensively applied in variant identification and
prioritization studies (Gylfe et al., 2013; Tanskanen et al., 2015;
Esteban-Jurado et al., 2015). Moreover, meta-prediction tools trying to
integrate outcomes from prediction tools have also been developed.
Examples are CONDEL (González-Pérez and López-Bigas, 2011),
CAROL (Lopes et al., 2012), CoNVEC (Frousios et al., 2013) or CADD
(Kircher et al., 2014; Rentzsch et al., 2018).
On the other hand, RNA splicing excise introns and splice exons. It is
essential that splicing sites are correctly recognized and, indeed, some
germline mutations involved in human disease predisposition alter this
process. In order to test a putative splicing alteration, either analysis of
the RNA patient or in silico prediction tools are also used (Jian et al.,
2014).
Huge amount of variants identified by NGS studies cannot be han-
dled roughly. Therefore, reliable tools are needed to prioritize those
potential deleterious variants into functional validation studies.
However, the wealth of pathogenicity prediction tools in the literature
could imply unknown divergences between methods, and implications
on this behalf shall be assessed (Cooper and Shendure, 2011). Studies to
find out prediction tools accuracy when applied to wide datasets or to
specific gene variants also have been performed (Mahmood et al., 2017;
Grimm et al., 2015; Frousios et al., 2013). Unfortunately, these bioin-
formatics tools do not offer a perfect solution for variant prioritization
and most researchers use several of them to reinforce their final can-
didate variant list. Benchmarking and optimization of all these pre-
diction methods will be essential to characterize the tremendous
number of future variants that owe to be identified.
3. Gene editing
In recent years, the CRISPR/Cas (Clustered Regularly Interspaced
Short Palindromic Repeats) gene editing technology has transformed
functional genomics, enabling researchers to potentially edit any de-
sired region of the genome. The molecular complex, based on the
adaptive defense system of bacteria and archaea, consists of two ele-
ments: an RNA sequence (guide RNA, gRNA) complementary to the
target DNA, and a nuclease (Cas) that recognizes the RNA/DNA hybrid
and performs a specific double-strand break (DSB) on it. Upon cleavage,
the target locus can be repaired through the error-prone non-homo-
logous end joining (NHEJ) pathway or by homologous recombination
(HR), which requires a DNA donor template. Hence, DNA repair
through NHEJ forces insertions and deletions, thereby inactivating the
target gene, while HR allows introducing specific changes in the
genome (Ran et al., 2013).
With this basis, the CRISPR/Cas system has been deeply explored
and adapted to become a versatile laboratory tool. Cas9, the most
commonly used nuclease, has been single (Cas9 nickase) and double
mutated (Cas9-null or dead-Cas9, dCas9) to improve its specificity and
targeting functions. The nickase performs single strand breaks due to a
unique active catalytic domain, and has a reduced off-target activity as
well as a higher in-situ editing efficiency (Komor et al., 2017). By
contrast, dCas9 has no endonuclease activity but can be specifically
targeted to any dsDNA sequence due to the gRNA/Cas9 interaction.
This CRISPR strategy, which is referred to as CRISPR interference
(CRISPRi) (Qi et al., 2013), can be used to recruit transcriptional acti-
vators and inhibitors to regulatory zones, to modulate epigenetic marks
and even to modify the genome architecture (Mali et al., 2013a).
Moreover, there are other Cas proteins with different protospacer ad-
jacent motifs (PAM) requirements, which increases targeting possibi-
lities (Rath et al., 2015). Its adaptability and enzymatic improvements
make the CRISPR system an efficient alternative to other functional
genomics approaches. Gene silencing by siRNAs and shRNAs is a fast
and inexpensive method, but generates an incomplete and temporary
gene inactivation, has unpredictable off-target effects and shows poor
reproducibility. Other gene editing strategies, such as TALEN (Tran-
scription Activator-Like Effector Nucleases) and ZFN (Zinc-finger nu-
cleases), perform accurate gene modifications but require a new nu-
clease design, synthesis, and validation for each target DNA (Gaj et al.,
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CRC modeling by CRISPR/Cas has allowed characterizing the her-
editary genes involved in the development of the disease, as well as the
somatic mutational events. In CRC cell lines, gene editing has confirmed
the effect of several point mutations in the proofreading domain of
POLE (Van Gool et al., 2018), the enhanced sensitivity to MEK in-
hibitors of homozygous KRASG13D mutants (Burgess et al., 2017), as
well as the role of MLH1, whose in vitro inactivation recreated a hy-
permutated profile (Germano et al., 2017). Non-coding RNAs involved
in CRC malignancy have also been CRISPR-inactivated, such as miR30-a
(Shen et al., 2017), CCAT2 (Yu et al., 2017) and CYTOR (Wang et al.,
2018), the latter by a precise whole-exon deletion. Furthermore,
CRISPR enhancer disruption (Cohen et al., 2017), transcriptional re-
pressor recruitment by dCas9 (Zhang et al., 2018) and multiplexed loss-
of-function screenings of epigenetic regulators (McCleland et al., 2016)
have allowed the identification of new therapeutic targets.
Several studies have already applied CRISPR/Cas in CRC organoids
to determine the pathogenicity of the most well-known mutations, as
well as to reconstruct the adenoma-carcinoma sequence. For instance,
the combination of gene disruption and precise gene editing strategies
has allowed generating quadruple (KRASG12D/APCKO/P53KO/
SMAD4KO) and quintuple (KRASG12V/PI3KCAE545K/APCKO/P53KO/
SMAD4KO) CRISPR-mutated CRC organoids (Drost et al., 2015;
Fumagalli et al., 2017; Matano et al., 2015). Mutations can also be
added to those already existing in the patients’ organoids. The CRC
serrated pathway has been reproduced in vitro by sequentially in-
troducing inactivation mutations in five different genes (TGFBR2,
RNF43, ZNRF3, CDKN2A, MLH1) on BRAFV600E organoids (Lannagan
et al., 2018). CRISPR has also been employed to enhance CRC organoid
generation by marking adult intestinal stem cells with Enhanced Green
Fluorescent Protein (EGFP), bypassing the lack of good commercial
antibodies to detect Leucine-rich repeat-containing G-protein coupled
receptor 5+ (LGR5+) cells (Cortina et al., 2017).
All these studies have demonstrated the power of CRISPR/Cas for
studying the functional consequences of genomic alterations in CRC.
Nevertheless, this genome editing system has not been much used to
study germline mutations in new candidate predisposition genes. Either
by gene inactivation or single base editing, CRISPR/Cas modeling could
be the key to decipher the pathogenicity of many variants of unknown
significance. For example, the CRISPR inactivation of NTHL1 in orga-
noids has been able to reproduce the mutational signature 30, pre-
viously observed in breast cancer patients with NTHL1 germline var-
iants (Drost et al., 2017) Additionally, high-throughput methods to
validate SNVs are also being developed, combining gene editing in
cancer cell lines coupled with molecular functional assays (Coggins
et al., 2017).
Before the CRISPR craze took over the genome editing field with the
announcement of the 2015 Breakthrough of the Year, zinc finger nu-
cleases (ZFN) and transcription activator like effector nucleases
(TALEN) were declared the “Method of the Year” in 2011 (Anonymous,
2012; Travis, 2015). The popularity of the CRISPR/Cas9 system stems
from the ease with which constructs expressing guide RNA's and the
Cas9 gene can be assembled. Yet there may still be some biotechnolo-
gical or therapeutic use for ZFN and TALEN. The ability of all three
programmable nucleases to cleave off-target sequences raise questions
about therapeutic safety (Pattanayak et al., 2013). The difficulty of
experimentally detecting off-target specificity because of the inherent
error rate of sequencing technology prevents an accurate comparison of
the different technologies (Akcakaya et al., 2018).
Recently the efficiency of genome editing by CRISPR/Cas9 was
linked to p53 mediated stress responses and cell cycle arrest
(Haapaniemi et al., 2018; Ihry et al., 2018). These studies showed that
in stem cells and in certain cell lines, p53 deficiency conferred an ad-
vantage in CRISPR/Cas9 mediated genome editing. This finding could
limit the editing of stem cell genomes because of the potential for se-
lecting p53 deficient clones that may have a higher risk of oncogenesis.
Whether ZFN and TALEN are also affected by the absence of p53 is not
yet clear. What is surprising is that a single CRISPR/Cas9 induced
double strand break in the genome can result in cell cycle arrest. It is
possible that occupancy of the cut site by different programmable nu-
cleases may induce different mechanisms of repair.
Delivery methods often limit the transfer of genome editing nu-
cleases to primary cells. In cases where gene transfer is not desired,
RNA or protein transfection may be a possibility. In the case of TALEN,
alternative direct delivery of proteins to target cells has been demon-
strated (Liu et al., 2014). With these limitations and potential ad-
vantages in mind, it is useful to revisit the now “old” mechanisms of
ZFN and TALEN mediated genome editing.
ZFN are biotechnological tools that started the genome editing
craze. These are chimeric nucleases that bind to DNA using several zinc
finger motifs (Kim et al., 1996). A comparison of transcriptional acti-
vator families in eukaryotes shows that in many species the zinc finger
family makes up the largest group (Tupler et al., 2001). Because zinc
finger DNA binding domains were the most common in nature, they
were the best choice to construct a chimeric nuclease. The crystal
structure of zinc finger motifs shows that these motifs contact DNA by
inserting a helix into the major groove and make four contacts, three in
the top strand and one in the bottom strand (Pavletich and Pabo, 1993).
A zinc atom coordinates this helix and two beta strands in each zinc
finger motif. Artificial ZFN typically fuse 3-4 N-terminal zinc finger
motifs to a C-terminal nuclease domain derived from the FokI restric-
tion endonuclease. FokI is a Type IIS restriction enzyme that recognizes
a non-palindromic site (GGATGN9/CCTACN13) and cleaves outside of
its recognition sequence. ZFN only contain the DNA cleaving domain of
the enzyme and not its DNA binding domain. DNA binding specificity of
a ZFN is purely directed by the zinc finger motifs. While zinc fingers
tend to recognize G-rich targets, a direct code that links amino acid
sequences in the DNA-recognizing alpha helix and the bound bases does
not exist. In fact, the specificity of the three bases recognized by each
motif is position and context dependent. As such, a zinc finger motif
that specifically binds to a three base pair sequence in the first position
of a four motif DNA binding domain does not necessarily bind to the
same sequence if it were present in the position corresponding to the
binding site of the second, third or fourth motif. Because of these lim-
itations, ZFN need to be assembled using complicated selection proce-
dures that requires the assembly of each ZFN in case by case fashion
(Maeder et al., 2009).
ZFN cut DNA when a heterodimer binds two target sequences
flanking a spacer sequence that gets cleaved by the FokI homodimer.
The optimum spacer length for a ZFN pair is 5 base-pairs. Various op-
timizations were made that prevent the formation of homodimers and
only result in the formation of heterodimers (Szczepek et al., 2007;
Miller et al., 2007). An early demonstration of a successful ZFN was a
study targeting human stem cells (Hockemeyer et al., 2009). ZFN-based
genome editing is not dead and gone. Several candidates are still in the
pipeline of biotechnology companies such as Sangamo Therapeutics as
of the last quarter of 2019.
TALEN are also dimers of site specific nucleases that use the FokI
restriction domain (Sanjana et al., 2012). The development of TALEN is
based on the identification of the DNA binding domain of the AvrBs3/
PthA or TAL (transcription activator-like) family proteins expressed in
the plant pathogenic bacteria belonging to the Xanthomonas spp. (Boch
and Bonas, 2010). Breaking the code of TALE DNA recognition was an
important finding that catapulted these tools into the limelight of
genome editing (Boch et al., 2009). Crystal structures demonstrating
how TALE proteins grab DNA was also a very exciting finding that re-
vealed a novel DNA binding mode for transcription factors (Mak et al.,
2012; Deng et al., 2012; Gao et al., 2012). 2011 was a year of revolu-
tions for the field of genome editing. The development of many tools to
assemble TALEN rapidly and efficiently shifted the interest of many
researchers in the field from ZFN to TALEN (Hockemeyer et al., 2011;
Miller et al., 2011; Cermak et al., 2011). Unfortunately, TALEN were
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only in the limelight for a short period of time, losing their popularity to
CRISPR by 2013 (Mali et al., 2013b; Ran et al., 2013).
Double strand breaks generated by either CRISPR/Cas9, ZFN or
TALEN result in a cellular DNA damage response that initiates the re-
pair of the cut site either by the error prone mechanism of NHEJ or HR
if donor DNAs are provided (Bibikova et al., 2001, 2003). While
CRISPR/Cas9 is easy to engineer, ZFN and TALEN may still be useful in
specifically recognizing and modifying target DNA sequences. A critical
advantage of TALEN may rely on the unusual helical structure of the
protein. DNA binding protein helices may find use as nanotechnological
carriers. Moreover, chimeric proteins that fuse alternative functional
domains to either ZFN or TALEN may still yield an advantage over
CRISPR/Cas9 (Guha and Edgell, 2017).
4. Model systems - patient-derived organoids
Functional studies based on already established cancer cell lines
have been shown to be insufficient and not representative of the het-
erogeneity and behavior of CRC in patients. Cell lines are exposed to a
passage-dependent accumulation of mutations and an extensive clonal
selection (Hidalgo et al., 2014; Pillai and Uthamanthil, 2017). More-
over, most cell-line based studies lack normal tissue-derived cells as a
reference and do not consider the impact of the stroma (Drost and
Clevers, 2018). In recent years, patient-oriented models have emerged
to fill the gap between cancer genetics and molecular diagnostics, en-
abling more personalized approaches (van de Wetering et al., 2015;
Weeber et al., 2017).
CRC organoids are self-organized 3D cell culture systems mainly
established from human colonic epithelium stem cells or induced
pluripotent stem cells (iPSC). They are propagated in vitro using dif-
ferent combinations of growth factors like Wnt/R-spondin1, EGF,
Noggin, ALK 4/5/7 and p38 inhibitors (Ohta and Sato, 2014; Sato et al.,
2011; Weeber et al., 2017). They preserve the in vivo structure and
genetic background of the original tissue, including their mutational
profile (Drost and Clevers, 2018), copy-number alterations (CNA) and
indels (Jung et al., 2011; Weeber et al., 2015), and the methylation
pattern (Roerink et al., 2018), that remain stable over time.
Patient-derived organoids (PDO) generation starts from cell sus-
pensions, which make possible to model organoids with genetic het-
erogeneity, clonal organoids or even genetically-modified organoids by
CRISPR technologies. These strategies can be used for modeling CRC
genetics and depict cancer initiation and progression, as well as intra-
tumor heterogeneity and diversification (Roerink et al., 2018). Several
studies have generated PDO harboring APC, P53, SMAD4, and KRAS
somatic mutations (Drost et al., 2015; Matano et al., 2015; Weeber
et al., 2015). Organoids with germline mutations in CRC hereditary
genes have also been developed, like APC (Crespo et al., 2017), MUTYH
(Lo et al., 2017) and MLH1, even recreating the mutational signature of
mismatch repair-deficient CRCs (Drost et al., 2017). However, it seems
that genetically engineered organoids do not fully mimic chromosomal
aberrations and DNA methylation patterns of the original tumors
(Salahudeen and Kuo, 2015).
Upon in vitro culturing and maintenance, organoids can also be
xenotransplanted in mice, either CRC-derived organoids (Roper et al.,
2018; Vlachogiannis et al., 2018) or genetically modified organoids
(Drost et al., 2015; Fumagalli et al., 2017; Matano et al., 2015). They
have been successfully implanted subcutaneously, orthotopically or in
the kidney capsule. Since they can be genetically edited, CRC PDO
models are the gold standard to study the genetic spectrum and mu-
tational processes that drive malignant transformation. They have also
been employed for drug screenings as they closely recapitulate patient
responses (Pauli et al., 2017; Vlachogiannis et al., 2018).
5. Model systems - patient-derived xenografts
Patient-derived xenografts (PDX) models consist of the implantation
of cancerous cell suspensions or small pieces of tumors derived from
primary surgical resection into immunocompromised mice, with sub-
sequent re-engraftment to successive generations. CRC PDXs are a very
reliable and precise approximation to the human tumor counterpart, as
genetic alterations are usually concordant with the parental tumor
(Bertotti et al., 2011; Julien et al., 2012; Seol et al., 2014) and are
maintained upon sequential passage (Kreso et al., 2013), including
mutations in classically CRC-associated genes, as well as CNA (Bertotti
et al., 2011) and small indels. Some PDX unique mutations have also
been detected, most of them related with the stroma components rather
than tumor cells, probably due to the coexistence and progressive re-
placement of human stroma by the murine one. Gene expression and
protein expression patterns are also well preserved, as well as the his-
tological structure, the lymphatic system and blood vasculature (Julien
et al., 2012). By now, the application of PDX models has been mainly
focused on drug discovery and personalized chemotherapy trials
through the so-called Avatar mice (Aparicio et al., 2015). Some studies
have revealed a surprising correlation between the response to che-
motherapy of CRC patients and the response of their corresponding
PDXs, as well as associations between gene mutations and drug re-
sistance (Bertotti et al., 2011; Hidalgo et al., 2014; Migliardi et al.,
2012).
PDO and PDX are cutting-edge tools that can be used to characterize
new CRC susceptibility genes. PDO are an easier tool to develop and
gene editing is affordable, although mutations affecting tumor-stroma
interactions are not reflected. On the other hand, PDX seem to better
resemble CRC tumors (Schütte et al., 2017) but imply high resource
consumption, and cancer initiation approaches are difficult. There is a
great need for setting up PDO and PDX biobanks to integrate the ex-
isting cohorts and establish new correlations between genetic markers
and drug sensitivity (van de Wetering et al., 2015), as well as to depict
the clinical heterogeneity of human CRC (Brown et al., 2016). Some of
the initiatives are the OncoTrack consortium (http://www.oncotrack.
eu) (Schütte et al., 2017), the Hubrecht Organoid Technology (HUB)
living biobank (http://hub4organoids.eu/), and the EurOPDX con-
sortium (https://europdx.eu/). Although considering PDO and PDX as a
clinical prognostic tool is still premature, the integration of these
models with NGS can help to monitor the genomic changes that trigger
CRC development and allow personalized therapy designs. Fig. 1 aims
to be a schematic of the different approaches described in the previous
sections.
6. Functional validation of genetic variants in CRC – hereditary
genes
The identification of pathogenic variants in genes predisposing to
CRC allows the clinical diagnosis of hereditary CRC syndromes. Aiming
to get a classification with clear clinical impact, integration of multiple
lines of evidence is needed, and the obtained by using functional assays
must be among them. Functional assays can evaluate the impact of a
variant at different molecular levels. In this section, we will briefly
review the main tools that have been used for the functional validation
of germline variants in genes predisposing to hereditary CRC.
At RNA level, genetic variants can affect transcription levels, mRNA
splicing or transcript stability. In silico predictions are usually used to
identify variants that can potentially alter the mRNA splicing (Jian
et al., 2014). Technical validation of these predictions includes assays
such as cDNA analysis in tissues from variant carriers and minigenes
(Castellsagué et al., 2010; Gaildrat et al., 2010, Borras et al., 2013).
Functional assays at the protein level are important in the evalua-
tion of the pathogenicity of a variant, provided that the evaluated
property is relevant to the mechanism of pathogenicity of the gene in
that disease (Richards et al., 2015; Nykamp et al., 2017). A variant can
affect the protein at different molecular steps (e.g. expression and sta-
bility, subcellular localization, complex formation, specific function)
(Fig. 2). To address the impact on the protein function of a hereditary
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CRC gene variant, gene-specific assays have been developed. It is im-
portant to consider whether the assay has been conducted under phy-
siological conditions, if the experimental model is human, if the func-
tion of the complete protein is evaluated, and if results are concordant
between different laboratories. Here, the main experimental ap-
proaches are reviewed.
Mismatch repair genes: Mismatch repair (MMR) system corrects
base-base mismatches and small insertion/deletions mainly introduced
by DNA polymerases during replication, but also mispairs formed
during recombination or chemically modified bases (Reyes et al., 2015).
Within the large diversity of assays used in functional assessment of
MMR variants, methods addressed to evaluate the MMR capability,
Fig. 1. In vivo, in vitro and in silico approaches in functional genomics. In silico methodologies include pathogenicity bioinformatics prediction tools, whereas in
vivo/in vitro cancer modeling ranges from gene silencing and overexression preliminary assays to more complex approaches such as gene editing and patient-derived
models.
Fig. 2. Functional testing of hereditary CRC gene variants. RT-PCR, reverse transcription PCR; qRT-PCR, quantitative real time PCR; WB, western blot; IHC, im-
munohistochemistry; IF, immunofluorescence; IP, immunoprecipitation; ASE, allele-specific expression.
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likely the most important function of a MMR protein, are proposed as
the gold standard to study MMR variants (Borràs et al., 2012;
Hinrichsen et al., 2015; Peña-Diaz and Rasmussen, 2016). In vitro cell-
free assays, consisting in a reconstitution assay using cell-free protein
extracts or human purified proteins together with nuclei extracts and a
substrate to repair, are currently the most commonly used (Plotz et al.,
2006; Ollila et al., 2008; Pineda et al., 2015; Drost et al., 2018), giving
advantages over former yeast-based in vivo or cell-based ex vivo assays
(Peña-Diaz and Rasmussen, 2016). Of note, recently a cell-free in vitro
MMR activity assay has been calibrated and validated, enabling its in-
tegration with in silico and clinical data in multifactorial likelihood
calculations of pathogenicity (Drost et al., 2018). Protein expression,
subcellular localization, heterodimer formation, sensitivity to methy-
lating agents, DNA mismatch binding or ATP processing have also been
assessed (Guerrette et al., 1998; Heinen et al., 2002; Ollila et al., 2008;
Borras et al., 2013; Hinrichsen et al., 2015).
MUTYH and NTHL1: MUTYH and NTHL1 are DNA glycosylases in-
volved in the base excision repair (BER) pathway, which is responsible
for the correction of base errors that are caused by oxidative damage,
alkylation, deamination or uracil misincorporation (Weren et al.,
2015). Whereas MUTYH is able of excising mispaired bases, NTHL1 has
both glycosylase and lyase activity. Thus, evaluation in vitro or in vivo
of DNA glycosylase activity in different models systems (E. coli, yeast,
human cell lines) has proven useful to assess functional impact of
MUTYH and NTHL1 variants (Yang et al., 2001; Shi et al., 2006; Turco
et al., 2013; Brinkmeyer and David, 2015; Komine et al., 2015; Robey-
Bond et al., 2017; Limpose et al., 2018). Besides, DNA binding affinity,
protein interactions and enzyme kinetics have also been evaluated
(D'Agostino et al., 2010; Kundu et al., 2010; Turco et al., 2013;
Brinkmeyer and David, 2015; Robey-Bond et al., 2017).
POLE and POLD1: Germline variants in POLE/POLD1 polymerases
linked to CRC predisposition are located within the exonuclease do-
main, affecting the 3′-5′ exonuclease (proof-reading) activity (Briggs
and Tomlinson, 2013; Palles et al., 2013; Nicolas et al., 2016). Due to
the high homology of the exonuclease domain of POLE and POLD1 in
human and yeast, most of the functional assays to evaluate variant
exonuclease repair activity are performed in yeast models (S. cerevisiae
or S. pombe) (Palles et al., 2013; Shinbrot et al., 2014; Barbari et al.,
2018; Castellsagué et al., 2018). The mutator phenotype is measured as
the mutation rate to canavanine resistance or amino acid-defective
yeast revertants (Mansour et al., 2001; Northam et al., 2010; Palles
et al., 2013; Kane and Shcherbakova, 2014; Barbari and Shcherbakova,
2017; Esteban-Jurado et al., 2017). Unfortunately, such yeast in vivo
assays are limited to variants in conserved residues of the exonuclease
domain. In addition, in vitro cell-free assays have been developed by
assessing the replication fidelity of purified proteins using lacZ forward
mutation assay or exonuclease repair activity (Ghodgaonkar et al.,
2014; Shinbrot et al., 2014).
APC and RNF43: APC gene codifies for a multifunctional protein
that controls beta-catenin turnover in the Wnt signaling pathway. One
of the most studied APC functions is the transcriptional activity medi-
ated by β-catenin-TCF-4 complex using a luciferase reporter assays
(Korinek et al., 1997; Azzopardi et al., 2008; Menendez et al., 2008).
Subcellular localization, either of APC or its binding proteins can also
be interrogated in transfected cells by immunostaining, immuno-
fluorescence or western blot after subcellular fractionation (Kohler
et al. 2008, 2009; Menendez et al., 2008). Other functions such as cell
migration and adhesion, apoptosis and protein interactions have also
been evaluated (Faux et al., 2004; Dikovskaya et al., 2007; Menendez
et al., 2008; Harris and Nelson, 2010).
RING finger protein 43 (RNF43) is an E3 ubiquitin ligase that inhibit
Wnt signaling by interacting with the Wnt receptors of the Frizzled
family (Loregger et al., 2015). In order to determine the effect of RNF43
variants on protein function, luciferase reporter assays have been used
in CRC cell lines transfected with RNF43 variants (Quintana et al.,
2018).
BMPR1A, SMAD4 and GREM1: BMPR1A and SMAD4 are genes as-
sociated with the TGF-β/BMP signal pathway (Cichy et al., 2014). In
this pathway, bone morphogenetic proteins (BMP) bind to BMPR1A,
which then dimerizes the receptor and leads to a phosphorylation
cascade. This phosphorylation cascade involves the phosphorylation of
SMAD proteins that then associate with oligomers of SMAD4, migrate
into the nucleus, and associate with DNA-binding proteins. SMAD4-
related gene expression leads to changes in genes important in cell
growth, differentiation, and apoptosis. Functional analysis of BMPR1A
and SMAD4 variants mainly assess the effect on signaling with either
BMP responsive element or SMAD luciferase reporter assays in trans-
fected cell lines (Kotzsch et al., 2008; Carr et al., 2012; Howe et al.,
2013). Subcellular localization, DNA binding, BMP-2 binding and pro-
tein stability -among others-have also been analyzed (Morén et al.,
2003; Kuang and Chen, 2004; Kotzsch et al., 2008; Howe et al., 2013).
In contrast, no gene-specific functional assays have been reported for
GREM1 variants except for monitoring its increased expression due to
the detected promoter duplication.
PTEN: PTEN gene encodes for a phosphatase that is essential for
regulating diverse biological processes, and through its lipid phospha-
tase activity regulates the phosphoinositide 3-Kinase/Akt/mTOR sig-
naling pathway (Pilarski et al., 2013). Phosphatase assays are employed
to study the catalytic activity of PTEN against phospholipid substrates
(Rodríguez-Escudero et al., 2011; Spinelli et al., 2015; Spinelli and
Leslie, 2015). PTEN stability and subcellular localization in S. cerevisiae
or mammalian cells have also been explored (Teresi et al., 2007;
Mighell et al., 2018; Mingo et al., 2018).
STK11: STK11 is a serine threonine kinase that regulates cell po-
larity and energy metabolism (Xu et al., 2013). Specific studies such as
evaluation of kinase activity, subcelullar localization, transcriptional
activity of downstream targets have been analyzed in variant function
evaluation studies (Nezu et al., 1999; Ylikorkala et al., 1999; Forcet
et al., 2005; Jiang et al., 2018).
Of note, repair pathway-specific mutational signatures and high
mutational burden have been recently described in some tumors as a
consequence of the underlying repair defect (Alexandrov and Stratton,
2014; Campbell et al., 2017; Drost et al., 2017; Pilati et al., 2017; Viel
et al., 2017). Therefore, it would be relevant to explore the value of
these somatic characteristics as a functional surrogate in germline
variant classification (Walsh et al., 2018).
In conclusion, well-established functional tests are mandatory to
support the pathogenicity of genetic variants in hereditary CRC genes.
In the last years, standardized classification systems have allowed im-
proving reproducibility and transparency of variant classification
(Thompson et al., 2014; Richards et al., 2015; Nykamp et al., 2017).
7. Functional validation of genetic variants in CRC – germline
candidate genes
In recent years, many research groups have proposed new candidate
genes for germline predisposition to non-affiliated familial CRC.
Although the majority of these studies did not tackle their functional
interpretation, a small number made experimental approaches to
identify new hereditary CRC genes. The aim of this section is to briefly
describe which genes have been deeply characterized through func-
tional analysis and which tools have been used. Table 2 summarizes
functional studies performed in candidate genes proposed for germline
predisposition to this neoplasm.
For those genes that encode catalytic activity domains, enzymatic
assays are an appropriate tool to evaluate the alteration of their parti-
cular function. One of the first candidate genes studied through func-
tional studies was EPHB2. The research group carried out in vitro kinase
assays via expression and immunoprecipitation of EPHB2 variants in a
human cancer cell line (Zogopoulos et al., 2008). Similarly, Guda et al.
and Evans et al. analyzed GALNT12 variants through a transferase ac-
tivity assay using radiolabeled oligosaccharides, in order to define their
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implication in glycosylation processes (Guda et al., 2009; Evans et al.,
2018). Point mutations can also modify protein-protein interaction
networks, which at the same time can modify their subcellular locali-
zation and the expression of downstream effectors. These features can
be assessed by Western Blot, immunofluorescence or co-im-
munoprecipitation assays, as performed for SMAD9 (Ngeow et al.,
2015), BUB1B (Hahn et al., 2008), SETD6 (Martín-Morales et al., 2017)
and SEMA4A (Schulz et al., 2014) variants. Genetic instability is an-
other main hallmark of hereditary cancer. The impact of the BUB1/
BUB3 variants on the mitotic checkpoint was analyzed using cytoge-
netic analysis (De Voer et al., 2013; Mur et al., 2018). WRN and ERCC6
variants were studied through helicase assays and chromatin re-
modeling assay. Its implication in DNA fragmentation was evaluated
using a comet assay (Arora et al., 2015). Adam et al., estimated MSH3
variants and its implication with genome instability through micro-
satellite analysis and immunocytochemistry of MMR proteins (Adam
et al., 2016). Many tumor suppressor genes are usually involved in
cellular growth and programmed cell death. In order to evaluate the
effect of UNC5C variants on apoptosis, Coissieux and colleagues per-
formed the TUNEL assay, which detects DNA fragmentation together
with Caspase-3 activity assay (Coissieux et al., 2011). Seguí et al. stu-
died the role of FAN1 variants on cell viability in response to mitomycin
C by cell counting analysis (Seguí et al., 2015). The effect of SEMA4A
variants on proliferation was analyzed by BrdU incorporation, and their
role on migration by cell exclusion zone assay (Schulz et al., 2014).
Finally, Bellido et al. deeply characterized BRF1 variants and its im-
plication in the apoptosis pathway via Annexin V staining assay. They
also carried out cell cycle assays by flow cytometry, clonogenic survival
and cell viability assays, and in order to support a low loss-of-function
effect, they also performed a dependent yeast growth assay (Bellido
et al., 2018).
In conclusion, it is essential to functionally corroborate the effect of
a selected candidate variant and its association with CRC. Although
there are multiple useful techniques to study the main cellular pro-
cesses, immunoblot, RT-PCR, immunocytochemistry and co-im-
munoprecipitation, together with flow cytometry and fluorescence
microscopy, are the most used tools due to their extreme versatility.
With proper sample preparation, these methods allow the evaluation of
the effect of a vast number of genetic variants.
8. Functional validation of genetic variants in CRC – somatic
variants
Somatic mutations in CRC have been under scrutiny due to their
importance in metastasis location and predicting patient's response to
therapies (Lipsyc and Yaeger, 2015). Driver somatic mutations in pri-
mary colorectal tumors are mostly found in KRAS (predominantly in
exon 3) (Andreyev et al., 2001), BRAF (Janakiraman et al., 2010), Wnt
effector genes (i.e. APC and FBXW7) (Morkel et al., 2015), TP53
(Janakiraman et al., 2010), PIK3CA and SMAD4 (Cancer Genome Atlas
Network, 2012). Gene editing approach has been used to model colo-
noscopy-based CRC studies, investigating various oncogenic genetic
variants, such as mutations in TP53, Wnt, TGFβ or EGFR pathways
(Fumagalli et al., 2017). This section is aimed at reviewing some
functional studies performed in these driver genes in order to further
characterize its alteration when mutated.
KRAS: Gene editing is broadly used to understand the underlying
pathways that become crucial for cancer cell survival. For instance, cell
growth mediators were recently characterized in KRAS-driven tumors
via genome-wide CRISPR screening. The genes that are selectively en-
hanced or inhibited after CRISPR-Cas9 introduction in CRC cells with
mutant KRAS (KRASMUT) and cells with wild-type KRAS (KRASWT) were
identified. Metabolic vulnerabilities of KRASMUT cell lines showed that
these cells are highly dependent on redox balance and nucleotide
synthesis (Yau et al., 2017). Introducing mutations in TP53 and APC
tumor suppressor genes in situ, following orthotopic transplantation of
APC, TP53 and KRAS mutant colon organoids, has been also used to
reproduce the entire spectrum of metastasis and tumor progression in
CRC (Roper et al., 2017).
PIK3CA: Mutations affecting PIK3CA, the catalytic subunit of PI3K
(phosphatidylinositide 3-kinase), have been reported in 10–20% of CRC
patients, mostly found in exons 9 and 20 (Ogino et al., 2014). Despite
having a minor effect of the overall prognostic of CRC, PIK3CA muta-
tions could be used as predictive biomarkers to manage patients and
expect successful response to targeted therapies, e.g. anti-EGFR (Epi-
dermal Growth Factor Receptor) therapy or adjuvant therapy with as-
pirin (Cathomas, 2014). Oncogenic PIK3CA mutations lead to gluta-
mine dependency in CRC cell lines. Glutamine deprivation induced
more apoptosis in these PIK3CA mutant cell lines (Hao et al., 2016).
CRC cells with mutated PIK3CA showed attenuation of apoptosis and
facilitated tumor invasion (Samuels et al., 2005).
TP53: The TP53 gene encodes a protein called tumor protein p53 (or
Table 2
Functional studies performed in candidate genes proposed for germline predisposition to colorectal cancer.
Function Functional techniques Candidate gene/s Reference
Enzyme activity In vitro kinase assays EPHB2 Zogopoulos et al. (2008)
Transferase activity assay GALNT12 Guda et al. (2009); Evans et al. (2018)
Helicase assays WRN Arora et al. (2015)
Chromatin remodeling assay ERCC6 Arora et al. (2015)
Protein-protein interaction Co-immunoprecipitation assays SMAD9; BUB1B; SETD6 Ngeow et al. (2015); Hahn et al., Martín-Morales et al. (2017)
Protein localization Immunofluorescence BUB1B, BUB1/BUB3 Hahn et al., Mur et al. (2018); De Voer et al., 2013
Cytogenetic analysis Aneuploidy study BUB1/BUB3 De Voer et al., 2013; Mur et al. (2018)
Mitotic checkpoint analysis BUB1/BUB3 Mur et al. (2018)
Chromosome segregation analysis BUB1/BUB3 Mur et al. (2018)
DNA fragmentation Comet assay WRN, ERCC6 Arora et al. (2015)
DNA repair Microsatellite analysis MSH3 Adam et al. (2016)
Immunocytochemistry of MMR proteins MSH3 Adam et al. (2016)
Apoptosis TUNEL assay UNC5C Coissieux et al. (2011)
Caspase-3 activity assay UNC5C Coissieux et al. (2011)
Annexin V staining assay BRF1 Bellido et al. (2018)
Proliferation and cell cycle 7-AAD/BrdU staining and flow cytometry SEMA4A; BRF1 Schulz et al. (2014); Bellido et al. (2018)
Flow cytometry BRF1 Bellido et al. (2018)
Clonogenic survival BRF1 Bellido et al. (2018)
Cell viability assays SEMA4A; BRF1 Schulz et al. (2014); Bellido et al. (2018)
Yeast growth assay BRF1 Bellido et al. (2018)
Migration Cell exclusion zone assay SEMA4A Schulz et al. (2014)
MMR, mismatch repair; Terminal deoxynucleotidyl transferase dUTP nick end labeling, TUNEL; 7-AAD, actinomycin D; BrdU, 5-bromo-2-deoxyuridine.
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p53) that acts as a tumor suppressor. TP53 mutation occurs in more
than half of CRC cases and mutations in this gene were found to be
more important in therapy response among affected patients (Iacopetta,
2003). Mutant TP53 led to elevated expression of several CRC cancer
stem cell markers such as CD44, LGR5, and ALDH (Wnt target genes).
Mutant p53 gained additional oncogenic functions along with losing its
tumor-suppressive function. Chemotherapy resistance in CRC patients
with mutated TP53 is due to ALDH1A1 over-expression that mediates
inhibition of apoptosis (Solomon et al., 2018). In addition to TP53,
PIK3CA mutation status also has predictive value for overall survival in
late stage CRC patients that undergo chemotherapy (Li et al., 2018).
APC: Adenomatous polyposis coli (APC) also known as deleted in
polyposis 2.5 (DP2.5) is a protein that in humans is encoded by the APC
gene. The APC protein is a negative regulator that controls beta-catenin
concentrations and interacts with E-cadherin, which is involved in cell
adhesion. APC mutations in CRC patients create truncated APC proteins
that not only have lost their tumor suppressive function but have also
gained other functional properties (similar to dominant negative effect
of mutant TP53), through affecting Wnt pathway, chromosome in-
stability and DNA repair, cell adhesion, and cell cycle control. These
changes were found to lead to CRC initiation and progression (L. Zhang
and Shay, 2017). In vitro studies on APC mutant cell lines have shown
that β-catenin inhibitory domain (CID) in APC determines tumor
transformation. USP7 (ubiquitin specific peptidase 7) depletion reverses
Wnt activation in APC mutant CRC, hence could be a potential target
for CRC patients with APC mutation (Novellasdemunt et al., 2017).
FBXW7: F-box/WD repeat-containing protein 7 is a protein that in
humans is encoded by the FBXW7 gene. FBXW7 functions as a ubiquitin
ligase and regulates a network of important oncoproteins (Davis et al.,
2014). Expression of this gene is lost in tumor tissue compared to their
adjacent normal tissue in 6–7.5% of CRC patients (Korphaisarn et al.,
2017). In vitro studies have shown genetic alteration in cells with
suppressed FBXW7. Cell proliferation is upregulated in these en-
gineered cells following enhanced expression of MYC and cyclin-E
proteins (Iwatsuki et al., 2010). In vitro deletion of FBXW7 promotes
chromosomal instability, and co-deletion of FBXW7 and TP53 created
highly aggressive, metastatic/invasive phenotype in vivo (Grim et al.,
2012).
SMAD4: Sporadic mutations in SMAD4 gene are present in
2.1%–20% of CRC patients, and are associated with poor prognosis and
less progression free survival time (Mehrvarz Sarshekeh et al., 2017).
Increased tumor growth and liver metastasis have been reported for
SMAD4 knockdown clones. Elevated Akt phosphorylation in SMAD4
deficient cell clones resulted in upregulation of anti-apoptotic proteins
(Bcl-2, Bcl-w and Survivin) and resistance to 5-fluorouracil-based
therapy (B. Zhang et al., 2014).
BRAF: The B-Raf protein is encoded by the proto-oncogene BRAF.
Mutations in this gene (mostly V600E) appear in 5–10% of metastatic
CRC (Korphaisarn and Kopetz, 2016). Cell line studies showed that
BRAF amplification in BRAF-mutated subsets of cells increases MEK
(mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase) phosphorylation, leading to resistance to MEK-inhibitors, sug-
gesting combination of BRAF and MEK inhibition as a therapeutic ap-
proach for this subgroup of patients (Corcoran et al., 2010).
There are also studies on other rare somatic mutations in CRC pa-
tients. Among them, POLE (catalytic subunit of DNA polymerase ep-
silon) (Guerra et al., 2017) and POLD1 (catalytic subunit of DNA
polymerase delta1) are investigated as important contributors to ul-
tramutation in CRC (Briggs and Tomlinson, 2013). Prognostic sig-
nificance of KDR (Kinase insert Domain Receptor) in CRC patients is
investigated in combination with the expression level of proteins such
as VEGFA (Vascular Endothelial Growth Factor A) and FLT1 (a cell-
surface receptor for VEGFA), pointing out the importance of thorough
comprehension of somatic mutations in predicting response for CRC
patients (Zhang et al., 2015).
Four of the most mutated genes in CRC (TP53, APC, SMAD4, KRAS)
were disrupted using CRISPR-Cas9 technology in human intestinal stem
cells to investigate the invasiveness of CRC cancer cells. Loss of both
TP53 and APC was shown to be sufficient for the emergence of aneu-
ploidy and tumor progression, nevertheless only quadruple-mutant or-
ganoids could produce poorly differentiated, highly proliferative, and
larger tumors in vivo (Drost et al., 2015).
9. Conclusion
NGS technologies constitute a recent revolution in science.
However, correct functional interpretation of the identified genetic
variants is nowadays the bottleneck for most studies to reach valid
conclusions. Available advances have been described in this chapter
and including bioinformatics, cell-based assays, CRISPR-Cas9, ZFN and
TALEN systems, organoids and xenograft models, that will permit to
move in this direction in the near future. Despite these important ad-
vances, the calibration of the calibration of the relative weight of each
evidences for every gene and the standardization of functional tests are
important challenges for the coming years.
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